Table 4.

Competing risk regression results comparing patients with and without SMN.

	Subhazard ratio	95% confidence interval	P value
Male	0.70	0.29−1.73	0.444
Other than stage 4 at diagnosis	0.43	0.15−1.17	0.099
MYCN amplified	0.59	0.16−2.17	0.158
Age at diagnosis in years	1.03	0.99−1.07	0.108
ASCT prior to MIBG	1.14	0.45−2.89	0.777
Months from ASCT to MIBG	1.01	0.99−1.02	0.505
Number of prior chemotherapy regimens	0.91	0.75−1.11	0.347
History of external beam radiation prior to MIBG	2.42	0.71−8.29	0.160
Age in years at 1st MIBG therapy	1.03	0.99−1.07	0.057
Months from diagnosis to 1st MIBG therapy	1.00	0.99−1.01	0.558
Bone marrow disease at initial MIBG therapy	0.60	0.24−1.51	0.236
Bone disease at initial MIBG therapy	0.36	0.13−0.99	0.049*
Soft tissue disease at initial MIBG therapy	2.67	0.78−9.13	0.118
Relapsed/progressive disease at first MIBG therapy (versus refractory/persistent)	0.40	0.15−1.06	0.065
One MIBG Tx (versus >1)	0.84	0.33−2.14	0.718
Cumulative MIBG dose in mCi/kg	0.99	0.96−1.03	0.842
Cumulative whole body radiation dose in cGy	1.00	0.99−1.01	0.409
Use of stem cell/bone marrow support after MIBG therapy	0.49	0.19−1.24	0.132

SMN, second malignant neoplasm; ¹³¹I-MIBG, iodine-131 metaiodobenzylguanidine; MYCN, V-Myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog; ASCT, autologous stem cell transplant; mCi, millicurie.